guest ::
| Home > Publications database > Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisation > print |
| Home > Publications database > Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisation > print |
| 001 | 904311 | ||
| 005 | 20220210164008.0 | ||
| 024 | 7 | _ | |a 10.1016/j.bmc.2021.116462 |2 doi |
| 024 | 7 | _ | |a 0968-0896 |2 ISSN |
| 024 | 7 | _ | |a 1464-3391 |2 ISSN |
| 024 | 7 | _ | |a altmetric:115774980 |2 altmetric |
| 024 | 7 | _ | |a pmid:34695709 |2 pmid |
| 024 | 7 | _ | |a WOS:000710815900002 |2 WOS |
| 037 | _ | _ | |a FZJ-2021-05881 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Falkenstein, Markus |0 0000-0001-9785-2100 |b 0 |
| 245 | _ | _ | |a Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisation |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2021 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1643205758_29329 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a Kein Zugriff auf Post-print |
| 520 | _ | _ | |a Alzheimeŕs disease (AD) is the most prominent neurodegenerative disorder with high medical need. Protein-protein-interactions (PPI) interactions have a critical role in AD where β-amyloid structures (Aβ) build toxic oligomers. Design of disease modifying multi target directed ligand (MTDL) has been performed, which disable PPI on the one hand and on the other hand, act as procognitive antagonists at the histamine H3 receptor (H3R). The synthetized compounds are structurally based on peptidomimetic amino acid-like structures mainly as keto, diketo-, or acyl variations of a piperazine moiety connected to an H3R pharmacophore. Most of them showed low nanomolar affinities at H3R and some with promising affinity to Aβ-monomers. The structure–activity relationships (SAR) described offer new possibilities for MTDL with an optimized profile combining symptomatic and potential causal therapeutic approaches in AD. |
| 536 | _ | _ | |a 5244 - Information Processing in Neuronal Networks (POF4-524) |0 G:(DE-HGF)POF4-5244 |c POF4-524 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Reiner-Link, David |0 0000-0003-1514-2215 |b 1 |
| 700 | 1 | _ | |a Zivkovic, Aleksandra |0 0000-0001-5034-7916 |b 2 |
| 700 | 1 | _ | |a Gering, Ian |0 P:(DE-Juel1)171922 |b 3 |
| 700 | 1 | _ | |a Willbold, Dieter |0 P:(DE-Juel1)132029 |b 4 |u fzj |
| 700 | 1 | _ | |a Stark, Holger |0 0000-0003-3336-1710 |b 5 |e Corresponding author |
| 773 | _ | _ | |a 10.1016/j.bmc.2021.116462 |g Vol. 50, p. 116462 - |0 PERI:(DE-600)1501507-5 |p 116462 - |t Bioorganic & medicinal chemistry |v 50 |y 2021 |x 0968-0896 |
| 909 | C | O | |o oai:juser.fz-juelich.de:904311 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)171922 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)132029 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-524 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Molecular and Cellular Information Processing |9 G:(DE-HGF)POF4-5244 |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-01-28 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1200 |2 StatID |b Chemical Reactions |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-28 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-28 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BIOORGAN MED CHEM : 2019 |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-01-28 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-01-28 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2021-01-28 |
| 920 | 1 | _ | |0 I:(DE-Juel1)IBI-7-20200312 |k IBI-7 |l Strukturbiochemie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|